Tevogen Bio Holdings Inc.

TVGNdata completeness 75%4 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'pretaxIncome'

i. The business — what you’d actually own

Figure	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—
Net income	$4.41M¹	−$60.5M²	−$13.7M³	−$26.3M³
Operating cash flow	−$215,395⁴	−$8.17M⁵	−$12M⁶	−$12.3M⁶
Capital expenditure	—	$133,000⁷	—	$64,439⁸
Free cash flow (derived)	—	−$8.3M⁵	—	−$12.4M⁶
Total debt	$0⁹	—	—	—
Cash & equivalents	$129,186¹⁰	$0¹¹	$0¹²	$0¹²
Diluted shares	2.4M	24.8M	2.9M	3.3M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$24.8

your share of equity

Profit it earned you last year

−$79.15

Free cash flow it threw off

−$37.33

Debt you’d be carrying

—

10 shares is a claim on −$24.8 of net worth that earned you −$79.15 and generated −$37.33 of cash last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 4y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+39% shares · 4y

Share count is up 39% over 4 years — owners have been diluted. Worth asking what they got for it.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts